The Pressure is On!

An Escape Room Experience

REGISTER NOW

Challenge Your Mind and Your Peers for a Spot on the Leaderboard!

DATE

March 1, 2024
March 2, 2024

TIME

9:30AM - 5:00PM
9:30AM - 4:00PM

Come and go as you please for this drop-in event

VENUE

SECO 2024
at Georgia World Congress Center (GWCC)

Booth 1805

WHERE WILL YOU BE ON THE LEADERBOARD?

WHERE WILL YOU BE ON THE LEADERBOARD?

You will have the opportunity to collect points and compare your score to that of your peers!
REGISTER NOW

By participating you will:

Gain insights into a new IOP-lowering treatment for patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT)
Apply your medical knowledge and
problem-solving skills to challenges
Network with fellow eye care professionals
Meet thought leaders in your field

Meet the Thought Leaders

Jean-Frédéric Chibret, MBA
(Host)
Fabrice Mercier, (Host)
Inventor of IYUZEH™(latanoprost ophthalmic solution) 0.005%*
Jason Bacharach, MD
Renee Bovelle, MD
David Solá-Del Valle, MD
Monique Barbour, MD
Rob Noecker, MD
Leo Siebold, MD
Leon Herndon, MD
Joseph Panarelli, MD
Aakriti (Aaki) Garg Shukla, MD
*Preservative-free latanoprost, launched over 10 years ago, is available in 46 countries, mostly under the brand name MONOPROST®, with about 1.5 million patients treated monthly.

WHERE DO I BEGIN?

To secure your spot, kindly register to embark on this exciting journey!

By doing so you will start accumulating points on the leaderboard immediately and get ahead of your peers.

REGISTER NOW*

Please use the same information here as you will to login during the event.

*NOTE: This event is for healthcare professionals. Due to PHRMA code, spouses and guests are not allowed, unless they are healthcare professionals.

As part of Thea Pharma Inc's commitment to complying with relevant legal & industry requirements, food, beverage, and other transfers of value will be tracked and reported in accordance with Physician Open Payments reporting, commonly referred to as the Sunshine Act.

Additionally, we regret that we may not be able to provide meals for healthcare professionals employed by the government and/or licensed in the state of Vermont or Minnesota. If you have questions, please notify a Thea Pharma US representative.

This program is non-CME.

Thea Pharma Inc. respects the personal information of the users of the form, in compliance with the laws protecting your personal data.

For more information on our privacy policy click here: https://theapharmainc.com/privacy-policy/

*NOTE: This event is for healthcare professionals. Due to PHRMA code, spouses and guests are not allowed, unless they are healthcare professionals.

As part of Thea Pharma Inc's commitment to complying with relevant legal & industry requirements, food, beverage, and other transfers of value will be tracked and reported in accordance with Physician Open Payments reporting, commonly referred to as the Sunshine Act.

Additionally, we regret that we may not be able to provide meals for healthcare professionals employed by the government and/or licensed in the state of Vermont or Minnesota. If you have questions, please notify a Thea Pharma US representative.

This program is non-CME.

Thea Pharma Inc. respects the personal information of the users of the form, in compliance with the laws protecting your personal data.

For more information on our privacy policy click here: https://theapharmainc.com/privacy-policy/

Thank you!
Your submission has been received!
Add this event to your calendar.
Thea Escape Room
The best escape rooms
March 1, 2024 9:00 AM
March 2, 2024 5:00 PM
SECO Exhibition Hall - Booth 1805, Altanta

Add event to calendar

AppleGoogleOffice 365OutlookOutlook.comYahoo

Oops! Something went wrong while submitting the form.

COMPLETE THE
FIRST ESCAPE ROOM
NOW

This online escape room will give you a taste of what's to come and get you even further ahead of your peers!

INDICATIONS AND USAGE
IYUZEH™ is a prostaglandin analogue indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Known hypersensitivity to latanoprost or any other ingredients in this product.

WARNINGS AND PRECAUTIONS
Pigmentation: Topical latanoprost ophthalmic products, including IYUZEH™ have been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes. Pigmentation is expected to increase as long as latanoprost is administered.

The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. After discontinuation of latanoprost, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes have been reported to be reversible in some patients. Patients who receive treatment should be informed of the possibility of increased pigmentation. The long-term effects of increased pigmentation are not known.Iris color change may not be noticeable for several months to years. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish. Neither nevi nor freckles of the iris appear to be affected by treatment. While treatment with IYUZEH™ can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly.

Eyelash Changes: Latanoprost ophthalmic products, including IYUZEH™ may gradually change eyelashes and vellus hair in the treated eye; these changes include increased length, thickness, pigmentation, the number of lashes or hairs, and misdirected growth of eyelashes. Eyelash changes are usually reversible upon discontinuation of treatment.

Intraocular Inflammation:
IYUZEH™ should be used with caution in patients with a history of intraocular inflammation (iritis/uveitis) and should generally not be used in patients with active intraocular inflammation because inflammation may be exacerbated.

Macular Edema: Macular edema, including cystoid macular edema, has been reported during treatment with latanoprost ophthalmic products, including IYUZEH™. IYUZEH™ should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

Herpetic Keratitis: Reactivation of herpes simplex keratitis has been reported during treatment with latanoprost. IYUZEH™ should be used with caution inpatients with a history of herpetic keratitis. IYUZEH™ should be avoided in cases of active herpes simplex keratitis because inflammation may be exacerbated.

Contact Lens Use: Contact lenses should be removed prior to the administration of IYUZEH™ and may be reinserted 15 minutes after administration.

ADVERSE REACTIONS
The following adverse reactions have been reported with the use of topical latanoprost products: iris pigmentation changes, eyelid skin darkening, eyelash changes (increased length, thickness, pigmentation, and number of lashes), intraocular inflammation (iritis/uveitis), and macular edema, including cystoidmacular edema.

DRUG INTERACTIONS
The combined use of two or more prostaglandins, or prostaglandin analogs including IYUZEH™ is not recommended. It has been shown that administration ofthese prostaglandin drug products more than once daily may decrease the IOP lowering effect or cause paradoxical elevations in IOP.

Click here for full Prescribing Information for IYUZEH™.

All the product and company names are trademarks or registered trademarks of their respective holders.



INDICATIONS AND USAGE
IYUZEH™ is a prostaglandin analogue indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Known hypersensitivity to latanoprost or any other ingredients in this product.

WARNINGS AND PRECAUTIONS
Pigmentation: Topical latanoprost ophthalmic products, including IYUZEH™ have been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes. Pigmentation is expected to increase as long as latanoprost is administered.

The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. After discontinuation of latanoprost, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes have been reported to be reversible in some patients. Patients who receive treatment should be informed of the possibility of increased pigmentation. The long-term effects of increased pigmentation are not known.Iris color change may not be noticeable for several months to years. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish. Neither nevi nor freckles of the iris appear to be affected by treatment. While treatment with IYUZEH™ can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly.

Eyelash Changes: Latanoprost ophthalmic products, including IYUZEH™ may gradually change eyelashes and vellus hair in the treated eye; these changes include increased length, thickness, pigmentation, the number of lashes or hairs, and misdirected growth of eyelashes. Eyelash changes are usually reversible upon discontinuation of treatment.

Intraocular Inflammation:
IYUZEH™ should be used with caution in patients with a history of intraocular inflammation (iritis/uveitis) and should generally not be used in patients with active intraocular inflammation because inflammation may be exacerbated.

Macular Edema: Macular edema, including cystoid macular edema, has been reported during treatment with latanoprost ophthalmic products, including IYUZEH™. IYUZEH™ should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

Herpetic Keratitis: Reactivation of herpes simplex keratitis has been reported during treatment with latanoprost. IYUZEH™ should be used with caution inpatients with a history of herpetic keratitis. IYUZEH™ should be avoided in cases of active herpes simplex keratitis because inflammation may be exacerbated.

Contact Lens Use: Contact lenses should be removed prior to the administration of IYUZEH™ and may be reinserted 15 minutes after administration.

ADVERSE REACTIONS
The following adverse reactions have been reported with the use of topical latanoprost products: iris pigmentation changes, eyelid skin darkening, eyelash changes (increased length, thickness, pigmentation, and number of lashes), intraocular inflammation (iritis/uveitis), and macular edema, including cystoidmacular edema.

DRUG INTERACTIONS
The combined use of two or more prostaglandins, or prostaglandin analogs including IYUZEH™ is not recommended. It has been shown that administration ofthese prostaglandin drug products more than once daily may decrease the IOP lowering effect or cause paradoxical elevations in IOP.

Click here for full Prescribing Information for IYUZEH™.

All the product and company names are trademarks or registered trademarks of their respective holders.